Literature DB >> 25219395

The effect of hydromorphone therapy on psychophysical measurements of the descending inhibitory pain systems in patients with chronic radicular pain.

Erica Suzan1, Roi Treister, Dorit Pud, May Haddad, Elon Eisenberg.   

Abstract

OBJECTIVE: Conditioned pain modulation (CPM) and offset analgesia (OA) are considered to represent paradigms of descending inhibitory pain modulation in humans. This study tested the effects of hydromorphone therapy on descending inhibitory pain modulation, as measured by changes from baseline in the magnitudes of CPM and OA.
DESIGN: Prospective evaluation.
SETTING: Institute of Pain Medicine, Rambam Health Care Campus.
SUBJECTS: Patients with chronic radicular pain.
METHODS: Thirty patients received 4 weeks of oral hydromorphone treatment at an individually titrated dose (mean ± standard deviation dose of 11.6 ± 4.8 mg/day). CPM and OA were assessed before and after hydromorphone treatment. CPM was assessed by subtracting the response to a painful phasic heat stimulus administered simultaneously with a conditioning cold pain stimulus, from the response to the same heat stimulus administered alone. The OA paradigm consisted of a three-temperature stimuli train (T1 = 49°C [5 seconds], T2 = 50°C [5 seconds], and T3 = 49°C [20 seconds]). The magnitude of OA was quantified by subtracting minimal pain scores obtained during T3 from the maximal pain scores obtained during T2.
RESULTS: CPM scores changed from a baseline of 17.7 ± 20.6 to 21 ± 20.4 following treatment, and OA scores changed from 7.8 ± 20.5 to 9.7 ± 14.6. Wilcoxon signed rank test indicated that these changes were not significant (CPM: P = 0.22; OA: P = 0.44). McNemar test revealed that the percentage of patients who exhibited a change in the direction of CPM or OA in response to hydromorphone treatment was not significant (CPM: P = 0.37; OA: P = 0.48).
CONCLUSIONS: These results suggest that the descending inhibitory pain modulation, as manifested in humans by CPM and OA, is unlikely to be mediated by hydromorphone therapy. Wiley Periodicals, Inc.

Entities:  

Keywords:  Conditioned Pain Modulation (CPM); Hydromorphone; Neuropathic Pain; Offset Analgesia (OA); Opioids; Pain Pathways

Mesh:

Substances:

Year:  2014        PMID: 25219395     DOI: 10.1111/pme.12565

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  6 in total

Review 1.  Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain.

Authors:  Lars Arendt-Nielsen; Søren T Skou; Thomas A Nielsen; Kristian K Petersen
Journal:  Curr Osteoporos Rep       Date:  2015-08       Impact factor: 5.096

2.  Family History of Alcohol Use Disorder as a Predictor of Endogenous Pain Modulation Among Moderate to Heavy Drinkers.

Authors:  Kyle M White; Lisa R LaRowe; Jessica M Powers; Michael B Paladino; Stephen A Maisto; Michael J Zvolensky; Stephen J Glatt; Joseph W Ditre
Journal:  J Pain       Date:  2021-12-31       Impact factor: 5.383

3.  Commentary: Novel Use of Offset Analgesia to Assess Adolescents and Adults with Treatment Resistant Endometriosis-Associated Pain.

Authors:  Claire E Lunde; Edina Szabo; Scott A Holmes; David Borsook; Christine B Sieberg
Journal:  J Pain Res       Date:  2020-11-02       Impact factor: 3.133

Review 4.  Monoaminergic and Opioidergic Modulation of Brainstem Circuits: New Insights Into the Clinical Challenges of Pain Treatment?

Authors:  Isaura Tavares; José Tiago Costa-Pereira; Isabel Martins
Journal:  Front Pain Res (Lausanne)       Date:  2021-07-05

5.  Greater Conditioned Pain Modulation Is Associated With Enhanced Morphine Analgesia in Healthy Individuals and Patients With Chronic Low Back Pain.

Authors:  Stephen Bruehl; Christopher R France; Amanda L Stone; Rajnish Gupta; Asokumar Buvanendran; Melissa Chont; John W Burns
Journal:  Clin J Pain       Date:  2021-01       Impact factor: 3.423

6.  Tapentadol extended release for the management of chronic neck pain.

Authors:  Domenico Billeci; Flaminia Coluzzi
Journal:  J Pain Res       Date:  2017-03-02       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.